Navigation Links
New medications show promise in treating drug-resistant prostate cancer
Date:4/7/2009

A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.

Of 30 men who received low doses of one the drugs in a multisite phase I/II trial designed to evaluate safety, 22 showed a sustained decline in the level of prostate specific antigen (PSA) in their blood. Phase III clinical trials are planned to evaluate the drug's effect on survival in a large group of patients with metastatic prostate cancer.

The drugs are second-generation antiandrogen therapies that prevent male hormones from stimulating growth of prostate cancer cells. The new compounds manufactured by the pharmaceutical company Medivation and known as MDV3100 and RD162 appear to work well even in prostate cells that have a heightened sensitivity to hormones. That heightened sensitivity makes prostate cancer cells resistant to existing antiandrogen therapies.

The drugs were discovered in the laboratory of Howard Hughes Medical Institute investigator Charles Sawyers at Memorial Sloan-Kettering Cancer Center in collaboration with chemist Michael Jung at UCLA. He and his colleagues described the development of the drugs and initial testing in an article posted online April 9, 2009, in Science Express, which provides electronic publication of selected Science articles in advance of print. Sawyers's team collaborated on the studies with researchers from the University of California Los Angeles, Oregon Health and Science University, University of Washington and Medivation.

About 186,000 new cases of prostate cancer are diagnosed each year in the United States. The male hormones testosterone and dihydrotestosterone -- also known as androgens -- spur the growth of prostate cells, and drugs that block the receptors for these hormones are the most common treatment for the disease in its advanced, metastatic stage. Antiandrogen drugs, such as bicalutamide, supp
'/>"/>

Contact: Jennifer Michalowski
michalow@hhmi.org
301-215-8576
Howard Hughes Medical Institute
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related biology news :

1. Device prevents potential errors in childrens medications
2. Study of successful drug targets could hasten development of new medications
3. Genetic variant mimics effect of heart failure medications
4. Hypertension and cholesterol medications present in water released into the St. Lawrence River
5. Innovative civil engineering application promises cleaner waters
6. New CPR promises better results by compressing abdomen, not Chest
7. Tiny tubes and rods show promise as catalysts, sunscreen
8. New genetic research into nicotine addiction shows promise for personalized treatment
9. Genetic ancestral testing cannot deliver on its promise, study warns
10. Sweet potato shines as new promise for small enterprise and hunger relief in developing countries
11. Summer-dormant tall fescue grass shows promise for pasture improvements

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)...s, red deer have been caught in the hunters, sight...ore than decorative. They are lethal weapons that ...rom The University of York, UK, has been intrigued...f a century and has become fascinated by the mecha... collaboration with Tomas Landete-Castillejos at t...
(Date:11/26/2009)...ylococcus Aureus ) and other drug-resistant bacter...ma prototype devices have been developed to offer ...ails. , Two prototype devices have been develope...(e.g. hands and feet) in hospitals and public spac...other to shoot bacteria-killing agents into infest...
(Date:11/25/2009)...ell Death Research Laboratory in the University of...he prestigious Johnson & Johnson Focused Funding g... cell damage in Parkinson,s disease. The award, wh...of innovation and excellence in science, was annou...s month at an event at the Hyatt Regency Hotel in ...
Breaking Biology News(10 mins):Tough yet stiff deer antler is materials scientist's dream 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2MEDISON Launches New Dedicated OB GYN 3D 4D Ultrasound System ACCUVIX V20 Prestige 57898 1MEDISON Launches New Dedicated OB GYN 3D 4D Ultrasound System ACCUVIX V20 Prestige 57898 2FDA Advisory Committee Unanimously Recommends Approval of XIAFLEX 28TM 29 for Treatment of Dupuytrens Disease 57893 1FDA Advisory Committee Unanimously Recommends Approval of XIAFLEX 28TM 29 for Treatment of Dupuytrens Disease 57893 2FDA Advisory Committee Unanimously Recommends Approval of XIAFLEX 28TM 29 for Treatment of Dupuytrens Disease 57893 3Reportlinker Adds Carbon Dioxide Monitors Report 10020 1Reportlinker Adds Carbon Dioxide Monitors Report 10020 2Reportlinker Adds Carbon Dioxide Monitors Report 10020 3Reportlinker Adds Carbon Dioxide Monitors Report 10020 4Reportlinker Adds Carbon Dioxide Monitors Report 10020 5Reportlinker Adds Carbon Dioxide Monitors Report 10020 6Reportlinker Adds Carbon Dioxide Monitors Report 10020 7Reportlinker Adds Carbon Dioxide Monitors Report 10020 8Reportlinker Adds Carbon Dioxide Monitors Report 10020 9
...s demonstrate enhanced cell killing compared to co...igen Therapeutics today announced the first publis...equence monoclonal antibodies (mAbs) produced in c...he chicken oviduct and deposited into egg white in...r, antibodies produced in this manner demonstrated...
...e if the outside world suddenly went dark every fe...s, even though they cause a similar reduction in t... not aware of the frequent mini-blackouts caused b...at visual sensitivity begins decreasing immediatel...ing this process have until now remained unclear. ...
...tch the tracking ability of dogs, we apparently ha...rding to a new study by scientists from the Univer... presented with odors to one nostril or the other ...rom, and functional magnetic resonance images of t... attention to the difference between what the left...
Other Biology News:First production of human monoclonal antibodies in chicken eggs published in Nature Biotechnology 2First production of human monoclonal antibodies in chicken eggs published in Nature Biotechnology 3Blink, and the brain misses it 2Study shows humans have ability to track odors, much like bloodhounds 2Study shows humans have ability to track odors, much like bloodhounds 3Study shows humans have ability to track odors, much like bloodhounds 4
(Date:11/30/2009)...FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasda...s of platinum-based anti-tumor compounds, termed b...potency and activity compared to currently availab... to overcome cisplatin-resistance in cancer cell l...d "Novel Bis-platinum Complexes Endowed with an Im...
(Date:11/30/2009)...DAM, November 30 Elsevie...dical and technical products and services,today a...nsive biomedical,database which holds over 20 mill...eer reviewed journals. , Embase has long ...ical,and pharmaceutical insights. Now, new develop...
(Date:11/27/2009)...FirstCall/ -- Stallergenes has been,granted Europe...d children,through a Mutual Recognition Procedure....een marketed, was the reference Member state. ,...lgium, Bulgaria, Cyprus, the,Czech Republic, Eston...ly,Latvia, Lithuania, Luxembourg, Malta, the Neth...
(Date:11/25/2009)...-- Biotech firm Replikins Ltd., which has analyzed...ic through the prediction, outbreak, and progress ...est biochemical analysis of the virus. The new dat...") virus has dropped from its peak of 3.7 (s.d. 4....ng of 2009 to resting non-epidemic levels this wee...
Breaking Biology Technology:New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5
...elligent, Inc. today,announced the launch of BaseP...handle DNA, RNA and protein data. A downloadable a...id and intuitive manipulation of,biological sequen...rmatics,professionals can now easily handle resear...rogramming or expensive genomics software packages...
... Inc. (Amex:,ADL) reported today that it has filed...mmission indicating that its Form 10-QSB for the s...led by November 14, 2007. However,AMDL expects to ...the time,allotted by the Rules. Gary L. Dreher, Pr... China is challenging and we need the additional t...
...rders, JACKSONVILLE, Fla., Nov. 13 An affiliate ...any") announced today that,its has recently produc...(TM), to launch the sale of the product in 450 7-E...to the Oregon border. The Company recently comple...on of AQISS(TM) to fill a backlog of orders as wel...
Other Biology Technology:Gentelligent, Inc. Asks 'Is your DNA in Excel?' 2AMDL Announces Filing of Extension on Third Quarter 2007 Form 10-QSB 2Phlo Affiliate Ships Product to Launch 450 7-Eleven Stores 2
Rabbit Anti-Presenilin 1 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Plastin L Monoclonal Antibody, Unconjugated, Clone LPL4A.1 from Abcam
...ast Cells are designed for use with the ProQuest T...MaV203 contains deletions in the endogenous GAL4 a...systems. The strain also has leu2 and trp1 mutatio.... MaV203 contains three GAL4 inducible reporter ge...
Feline IL-2 ELISpot Kit from R&D Systems
Biology Products: